A phase I/II study in patients with relapsed AML presented consistent clinical data, reporting the correlation of in vivo evidence of disruption of the CXCR4/CXCL12 axis with encouraging rates of remission (NCT00512252) [146]. Here, CXCR4 is linked to acute myeloid leukemia.